REGISTER
OCC 2026 | China’s Rise in Cardiovascular Innovation
Dr. Fernando Alfonso reflects on China’s rapid rise in cardiovascular innovation, highlighting the growing visibility of Chinese research in major international journals and the increasing presence of Chinese cardiovascular devices in Europe. He notes that high-quality Chinese trials are now helping shape global treatment pathways.

In OCC 2026 Quest for Truth roundtable, leading cardiovascular experts gather to discuss “Innovation: The Voyage Begins — From Chinese Stents to the Eastern Power in Global Cardiovascular Innovation”. The session is hosted by Prof. Gang Wu, Shanghai General Hospital, and co-moderated by Prof. Qixia Jiang, Shanghai General Hospital. Quest for Truth is honored to welcome the distinguished interview guest: Dr. Fernando Alfonso, Hospital Universitario de la Princesa.

In this segment, the conversation turns to milestones in China’s cardiovascular innovation journey, from following global advances to contributing original research, devices, and clinical evidence. Prof. Gang Wu asks Dr. Fernando Alfonso what he sees as the most significant marker of China’s rise in cardiovascular innovation over the past decade.

Dr. Fernando Alfonso highlights two major changes: the growing visibility of Chinese research in high-impact international journals, and the increasing presence of Chinese cardiovascular devices in Europe. He notes that international physicians are now learning not only from Chinese studies, but also from Chinese-developed technologies that have entered clinical practice and commercial use beyond China.

When asked about Chinese trials, Dr. Alfonso emphasizes that many studies from China are now making an important impact on global cardiovascular science. He points to the high quality, large sample sizes, impressive results, and strong safety and efficacy data of Chinese clinical trials, including research on drug-coated balloons and antiplatelet therapy strategies, as evidence that China is becoming an increasingly important force in shaping cardiovascular treatment pathways.

0
0
Loading